Abstract Since the introduction of high-resolution microarray technologies, it has become apparent that structural chromosomal rearrangements can lead to a wide variety of clinical manifestations, including developmental delay/intellectual disability (DD/ID). It has been shown previously that the diagnostic yield of genome-wide array-based identification of submicroscopic alterations in patients with ID varies widely and depends on the patient selection criteria. More attempts have recently been made to define the phenotypic clues of pathogenic copy number variants (CNVs). The aim of this study was to investigate a well-phenotyped cohort of patients with DD/ID and determine whether certain clinical features may serve as indicators for pathogenic CNVs. A retrospective analysis was conducted for patients with DD/ID (n=211) who were tested using genome-wide chromosomal microarray technologies and a review of the clinical data was performed. Pathogenic CNVs were detected in 29 patients. In comparison with individuals who had normal molecular karyotyping results (n=182), malformations of the musculoskeletal system; congenital malformations of the CNS (particularly hydrocephalus and congenital malformations of the corpus callosum); minor anomalies of the eye, face, and neck subgroup (particularly downward-slanting palpebral fissures, minor anomalies of the ear, and micrognathia); brachydactyly; and umbilical hernia were more common in patients with chromosomal alterations. A multivariate logistic regression analysis allowed the identification of three independent pathogenic CNV predictors: congenital malformations of the corpus callosum, minor anomalies of the ear, and brachydactyly. Insights into the chromosomal phenotype may help to increase the diagnostic yield of microarray technologies and sharpen the distinction between chromosomal alterations and other conditions.
Introduction
Genetic abnormalities are the main cause of intellectual disability. Using the phenotype-first approach, an experienced clinician can define the clinical diagnosis from 17.2 % (Majnemer and Shevell 1995) to 34.2 % (Battaglia et al. 1999 ) of patients with intellectual disability. In 14-18 % of the remaining patients, the diagnosis can be revealed using genome-wide chromosomal microarray technologies such as array-based comparative genomic hybridization (aCGH) and single-nucleotide polymorphism (SNP) arrays (Hochstenbach et al. 2011) . Since the introduction of high-resolution microarray technologies, it has become apparent that structural chromosomal rearrangements can lead to a wide variety of clinical manifestations, including developmental delay/intellectual disability (DD/ID), congenital anomalies, and dysmorphic features. It has been recommended that an array-based screen for genomic deletions and duplications, the so-called copy number variations (CNVs), should be the first-tier cytogenetic diagnostic test for patients with DD/ID, autism spectrum disorders (ASD), and multiple congenital anomalies (MCA) (Bartnik et al. 2014; Gijsbers et al. 2009; Miller et al. 2010 ).
The review by Hochstenbach et al. (2011) has shown that the diagnostic yield of genome-wide array-based identification of submicroscopic gains and losses in ID/MCA patients is 13.6 %, but with a wide range (9-50 %). As expected, the studies of unselected patients had a lower diagnostic yield (10.9 %) than the studies of selected patients. The increasing amount of genomic data signifies complexity in the genotype and phenotype relationship and draws attention to the need for more detailed phenotypic characterization. Increasing attempts have recently been made to define the phenotypic clues of pathogenic CNVs. Vulto-van Silfhout et al. (2013) showed, in a large cohort of phenotypically well-characterized patients, that de novo and inherited CNVs can be associated with a clinically relevant phenotype. Several clinical features were more frequent in patients with pathogenic CNVs according to Shoukier et al. (2013) . Sajan et al. (2013) reported that both rare and de novo CNVs are prevalent in agenesis of the corpus callosum, but not in other brain malformations. Detailed phenotypic characterization of additional patients may aid in enlarging the phenotypic spectrum associated with clinically relevant CNVs.
The aim of our study was to investigate a well-phenotyped cohort of patients with DD/ID who has been investigated using genome-wide chromosomal microarray technologies and determine whether certain clinical features may serve as indicators for pathogenic CNVs. Detailed analysis of the clinical and molecular data of patients with DD/ID revealed phenotypic clues aiding the detection of pathogenic CNVs. Insights into the chromosomal phenotype may help to increase the diagnostic yield of chromosomal microarray technologies and sharpen the distinction between chromosomal and other conditions, including monogenic, epigenetic, and multifactorial conditions.
Patients and methods
A retrospective analysis was conducted for patients with DD/ ID (n=211) who were tested using genome-wide chromosomal microarray technologies. The main selection criterion for molecular karyotyping was unknown etiology of DD/ID (Table 1) . Both syndromic and non-syndromic cases were included. The DD/ID levels of patients ranged from mild to profound. Previously performed conventional karyotyping, targeted fluorescence in situ hybridization (FISH), molecular tests, and investigations for metabolic disorders revealed no causative anomaly. The detailed clinical history and data of physical examinations of all patients were reviewed. Informed consent for genetic investigations was obtained from the participating families. The study was approved by the Vilnius Regional Biomedical Research Ethics Committee.
DNA from the patients was isolated using the phenolchloroform extraction method. Diagnostic screening was performed using aCGH with 44 K (n=10), 105 K (n=102), and 400 K (n=76) oligo chips (Agilent Technologies, Santa Clara, CA, USA) or SNP arrays with 300 K (n=12) and 700 K (n=11) platforms (Illumina Inc., San Diego, CA, USA), according to the manufacturer's instructions. FISH and real-time polymerase chain reaction (PCR) were used for the confirmation of gene dose imbalances and investigation of parental samples. The pathogenicity of the CNVs was assessed using the guidelines described by Lee et al. (2007) .
Statistical analysis was performed using IBM SPSS Statistics 20 software (IBM, Armonk, NY, USA). The clinical data of patients with chromosomal alterations were compared with those having normal molecular karyotyping results using the χ 2 test. Fisher's exact test rather than the χ 2 test was used when one or more of the cells had an expected value of less than 5. The statistical relationship between variables was estimated using the Spearman correlation coefficient. Multivariate logistic regression analysis was performed to determine the predictors of pathogenic CNVs, using the result of molecular karyotyping as a dependent variable. A p-value of <0.05 was considered statistically significant.
Results
Of the total sample of 211 patients, 148 (70.1 %) were males and 63 (29.9 %) were females. One hundred and eighty-one (85.8 %) patients had syndromic DD/ID, and in the remaining 30 cases, the DD/ID was non-syndromic. One hundred and thirteen (53.6 %) patients were under 5 years of age and were defined as having DD. Severe DD/ID was estimated accordingly in 9.7 % and 19.4 % of the patients.
Thirty-six pathogenic CNVs in 29 of 211 patients (13.7 %) were identified, and they ranged in size from 0.26 to 18.42 Mb, with median and mean sizes of 3.12 Mb and 5.11 Mb, respectively. Twenty-four of all detected pathogenic CNVs were deletions and 12 were duplications. Known syndromes were diagnosed in 31 % of patients with pathogenic CNVs (9/29), novel CNVs were detected in 45 % of patients with pathogenic CNVs (13/29), and the rest of the patients (24 %) had unbalanced translocations or other complex chromosomal abnormalities (7/29). The clinical and genetic information of all patients with pathogenic CNVs is presented in Table 2 . Analysis of the main characteristics of the genealogies and personal histories of patients with pathogenic CNVs (group A) and without chromosomal alterations (group B) revealed no statistically significant differences between these two groups. In the total sample of 211 patients, 798 phenotypic features were registered (median of 4 per patient), and, of them, 192 (24.1 %) were congenital anomalies (classified according to Q-Chapters with BPA extension, version 23 June 2008) and 606 (75.9 %) were minor anomalies (according to the EUROCAT list 'Minor Anomalies for Exclusion'). The evaluation of the clinical data in patients with pathogenic CNVs compared to patients without chromosomal alterations is shown in Fig. 1 . DD/ID was syndromic in all cases of pathogenic CNVs, while 16.5 % of patients without chromosomal alterations had isolated DD/ID, and this difference was statistically significant (p=0.018). At least one congenital anomaly was detected significantly more frequently in patients with chromosomal alterations (72.4 % in group A vs. 45.1 % in group B, p=0.005). At least one minor anomaly was present in 84.1 % of patients with normal molecular karyotyping results and all patients with pathogenic CNVs; this difference was statistically significant (p=0.01). Three or more minor anomalies were also more frequent in patients with chromosomal alterations (69 % in group A vs. 45.6 % in group B, p=0.016). A significant difference between patients with and without pathogenic CNVs was determined when analyzing the frequency of congenital malformations of the nervous system (48.3 % in group vs. 28 % in group B, p=0.026). The findings of the statistical analysis also indicated the increased frequency of pathogenic CNVs in patients with congenital malformations of the musculoskeletal system (p=0.037) and minor anomalies of the eye, ear, face, and neck subgroup (p= 0.003). Several statistically significantly phenotypic traits were more frequent in patients with pathogenic CNVs, including hydrocephalus (p=0.023), congenital malformations of the corpus callosum (p=0.014) [observed by brain magnetic resonance tomography (MRT) or computed tomography (CT) investigation], downward-slanting palpebral fissures (p= 0.008), minor anomalies of the ear (p=0.002), micrognathia (p=0.004), brachydactyly (p=0.005), and umbilical hernia (p=0.008). Café au lait spots could more frequently be found in patients without pathogenic CNVs (p=0.023).
Multivariate logistic regression analysis was performed to determine the predictors of pathogenic CNVs. Three independent predictors of pathogenic CNVs were determined: congenital malformations of the corpus callosum, minor anomalies of the ear, and brachydactyly, increasing the risk of pathogenic CNVs by 8.5, 3.5, and 7.4 times, respectively (Table 3) .
A classification tree plot (dendrogram) revealed wellseparated clusters when all the significantly different anomalies between the groups of patients that were analyzed were included (Fig. 2) . The dendrogram shows the similarity between patients, where individuals in the same cluster are more similar regarding their phenotypic features to each other than to patients in other clusters. The dendrogram revealed that the cohort of patients with DD/ID in the study was not homogeneous phenotypically, but clear separation between patients with and without pathogenic CNVs was not obtained.
Discussion
In this study, a retrospective review of the clinical and molecular data of 211 patients with DD/ID tested using genomewide chromosomal microarray technologies was performed, aiming to determine whether patients with pathogenic CNVs can be assigned to a distinct clinical subgroup. The estimated yield of molecular karyotyping of patients with DD/ID in this study is 13.7 %. This result is consistent with previously reported results (5-15 %) (Shaffer et al. 2006; Lu et al. 2007 ). Our total detection rate of pathogenic CNVs other than those associated with known microdeletion/microduplication syndromes is 9.5 % (20/29). Molecular karyotyping, therefore, provides a unique possibility in many patients with DD/ ID to formulate a genetic diagnosis, which could not be done by the phenotype-first approach. The detection rate of pathogenic CNVs can be influenced by the preselection criteria of the patients and the median spacing of the probes in the platform used. The recruitment of patients in this study was not selective (regarding the severity of DD/ID and presence of congenital malformations and minor anomalies) and likely represented the general population of patients with unknown causes of DD/ID. Unless several different platforms were used for molecular karyotyping, most patients were investigated using high-resolution platforms (201/211). Since highresolution molecular karyotyping revealed small CNVs (<500 kb in size) in 1 % of patients (2/201), the possibility of undetected small pathogenic CNVs in the remaining ten patients tested by low-resolution arrays was about 0.1 % and was considered insignificant.
The leading known cause of DD/ID is currently chromosomal alterations. The clinical implementation of genomewide chromosomal microarray technologies has revolutionized the diagnosis of patients with syndromic and nonsyndromic ID. The common use of molecular karyotyping led to an increase of known benign as well as disease-causing pathogenic CNVs (Weise et al. 2012 ). Many diagnostic genetic laboratories have started to implement chromosomal (Bonnet et al. 2010) arr 7p22.1 (5,337,072-6,316,915)x3 dn 0.98 14 years, ♀; mild ID, obesity, macrocephaly, internal hydrocephalus, craniofacial dysmorphism, tapering fingers, flat arches of feet, scoliosis (Chui et al. 2011; Preiksaitiene et al. 2012a) arr 7q35q36.1 (146, 392, 441, 454) x1 dn 3.05 11 years, ♂; moderate ID, epilepsy, macrocephaly, low-set and protruding ears, narrow palpebral fissures, thick lower lip, pectus carinatum, limited movements of knees and elbows (Poot et al. 2010) microarray technologies into a routine diagnostic setting. Still, specific phenotypic clues might be helpful towards the detection of pathogenic CNVs, as not all laboratories can perform this test on every patient with DD/ID and the yield of molecular karyotyping can be influenced by the preselection criteria of the patients.
Although the clinical features of the microdeletion/ microduplication syndromes are highly diverse and complex, a pattern of dysmorphic features, congenital malformations, intrauterine and postnatal growth retardation, and DD/ID have long been known as the main indicators of chromosomal abnormalities (Schinzel 1993) . According to Schinzel (1993) , several congenital malformations are more common in patients with autosomal chromosomal alterations, including certain brain malformations, omphalocele, etc. Reports by Shoukier et al. (2013) and Vulto-van Silfhout et al. (2013) provided additional evidence that specific clinical features may be associated with clinically relevant CNVs.
In our study, retrospective statistical analysis of the clinical data revealed that syndromic DD/ID and specific congenital malformations, as well as minor anomalies, were more frequent in patients with pathogenic CNVs. The findings indicate the increased frequency of pathogenic CNVs in patients with congenital malformations of the central nervous system (CNS, particularly hydrocephalus and congenital malformations of Fig. 1 Evaluation of the clinical data of patients with pathogenic copy number variants in comparison with patients with normal molecular karyotyping results (CA congenital anomaly, MA minor anomaly, pCNVs pathogenic copy number variants) the corpus callosum), malformations of the musculoskeletal system, and minor anomalies of the eye, face, and neck subgroup (particularly downward-slanting palpebral fissures, minor anomalies of the ear, and micrognathia). Brachydactyly and umbilical hernia were also more common in patients with chromosomal alterations. A multivariate logistic regression analysis allowed the identification of three independent predictors of pathogenic CNVs: congenital malformations of the corpus callosum, minor anomalies of the ear, and brachydactyly. While these observations are suggestive, additional studies will be needed for more detailed characterization of this association. The increased frequency of corpus callosum malformations in patients with pathogenic CNV coincides with a large-scale CNV analysis involving common brain malformations recently reported by Sajan et al (2013) . The research states that both rare and de novo CNVs are prevalent in corpus callosum agenesis, but not in cerebellar hypoplasia or polymicrogyria. These differences may be explained by the influence of nongenetic factors or single gene mutations in patients with brain malformations other than corpus callosum agenesis (Sajan et al. 2013) . The prevalence of corpus callosum agenesis occurs in less than 1 % of the general population and in approximately 2-3 % of individuals with developmental disabilities (Bedeschi et al. 2006) . It has been shown previously that facial dysmorphism was significantly more prevalent in patients with de novo CNVs (Vulto-van Silfhout et al. 2013 ). Our results specify that minor anomalies of the ears could be one of the most important indicators for pathogenic CNVs. The possible reason for altered morphogenesis of the external ear is the abnormal development of the neurocranial structures, i.e., the brain (Kagurasho et al. 2012) .
The results of this study enhanced the knowledge about the phenotypic features of patients with pathogenic CNVs. Description of additional cohorts with detailed clinical and molecular information will, further, make some new insights into the chromosomal phenotype. The information about the specific spectrum of minor anomalies and congenital malformations in patients with pathogenic CNVs may be helpful in selecting patients for molecular karyotyping and increasing the diagnostic yield of this investigation. Detailed description of the phenotypes of patients with pathogenic CNVs is essential for the adequate use of genome-wide chromosomal microarray results.
